BioLine RX Ltd
BLRX3.040USD
+0.080+2.70%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
13.23MMarket Cap
LossP/E TTM
More Details of BioLine RX Ltd Company
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
BioLine RX Ltd Info
Ticker SymbolBLRX
Company nameBioLine RX Ltd
IPO dateJan 30, 2007
CEOSerlin (Philip Adam)
Number of employees28
Security typeDepository Receipt
Fiscal year-endJan 30
AddressModi'in Technology Park
CityMODIIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code7177871
Phone97286429100
Websitehttps://www.biolinerx.com/
Ticker SymbolBLRX
IPO dateJan 30, 2007
CEOSerlin (Philip Adam)
Company Executives of BioLine RX Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Hillit Mannor Shachar
Dr. Hillit Mannor Shachar
Vice President - Business Development
Vice President - Business Development
--
--
Dr. Sandra Panem, Ph.D.
Dr. Sandra Panem, Ph.D.
Director
Director
--
--
Mr. Philip Adam (Phil) Serlin
Mr. Philip Adam (Phil) Serlin
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Michael J. Anghel
Dr. Michael J. Anghel
Director
Director
--
--
Dr. Ella Sorani
Dr. Ella Sorani
Vice President - Development
Vice President - Development
--
--
Dr. Barbara-Jean (BJ) Bormann
Dr. Barbara-Jean (BJ) Bormann
Director
Director
--
--
Mr. Gal Cohen
Mr. Gal Cohen
Independent Director
Independent Director
--
--
Ms. Nurit Benjamini
Ms. Nurit Benjamini
External Director
External Director
--
--
Ms. Mali Zeevi
Ms. Mali Zeevi
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Hillit Mannor Shachar
Dr. Hillit Mannor Shachar
Vice President - Business Development
Vice President - Business Development
--
--
Dr. Sandra Panem, Ph.D.
Dr. Sandra Panem, Ph.D.
Director
Director
--
--
Mr. Philip Adam (Phil) Serlin
Mr. Philip Adam (Phil) Serlin
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Michael J. Anghel
Dr. Michael J. Anghel
Director
Director
--
--
Dr. Ella Sorani
Dr. Ella Sorani
Vice President - Development
Vice President - Development
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hong Seng Technology Ltd
3.92%
Citadel Advisors LLC
0.23%
UBS Financial Services, Inc.
0.15%
Morgan Stanley & Co. LLC
0.12%
Intracoastal Capital, L.L.C.
0.07%
Other
95.51%
Shareholders
Shareholders
Proportion
Hong Seng Technology Ltd
3.92%
Citadel Advisors LLC
0.23%
UBS Financial Services, Inc.
0.15%
Morgan Stanley & Co. LLC
0.12%
Intracoastal Capital, L.L.C.
0.07%
Other
95.51%
Shareholder Types
Shareholders
Proportion
Corporation
4.00%
Investment Advisor
0.25%
Hedge Fund
0.23%
Research Firm
0.16%
Other
95.37%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
62
27.70K
3.92%
--
2025Q3
65
27.70K
4.05%
-38.51K
2025Q2
64
66.21K
2.82%
+56.76K
2025Q1
62
9.46K
4.78%
-168.28K
2024Q4
61
51.31K
6.91%
-11.13K
2024Q3
60
62.45K
12.93%
-43.93K
2024Q2
64
107.06K
9.39%
+72.30K
2024Q1
62
34.99K
9.95%
-145.17K
2023Q4
66
30.65K
11.57%
-4.56K
2023Q3
69
34.99K
12.67%
+3.06K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hong Seng Technology Ltd
170.73K
3.92%
--
--
Mar 16, 2025
Citadel Advisors LLC
14.95K
0.34%
+14.95K
--
Jun 30, 2025
Morgan Stanley & Co. LLC
643.00
0.01%
-701.00
-52.16%
Jun 30, 2025
Intracoastal Capital, L.L.C.
3.13K
0.07%
+3.13K
--
Mar 16, 2025
Rhumbline Advisers Ltd. Partnership
4.28K
0.1%
+2.75K
+179.41%
Jun 30, 2025
Wells Fargo Advisors
1.75K
0.04%
-1.25K
-41.67%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
900.00
0.02%
--
--
Jun 30, 2025
Nemes Rush Group, LLC.
250.00
0.01%
-50.00
-16.67%
Jun 30, 2025
GWM Advisors LLC
107.00
0%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
Date
Type
Ratio
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
FAQs
Who are the top five shareholders of BioLine RX Ltd?
The top five shareholders of BioLine RX Ltd are:
Hong Seng Technology Ltd holds 170.73K shares, accounting for 3.92% of the total shares.
Citadel Advisors LLC holds 14.95K shares, accounting for 0.34% of the total shares.
Morgan Stanley & Co. LLC holds 643.00 shares, accounting for 0.01% of the total shares.
Intracoastal Capital, L.L.C. holds 3.13K shares, accounting for 0.07% of the total shares.
Rhumbline Advisers Ltd. Partnership holds 4.28K shares, accounting for 0.10% of the total shares.
Hong Seng Technology Ltd holds 170.73K shares, accounting for 3.92% of the total shares.
Citadel Advisors LLC holds 14.95K shares, accounting for 0.34% of the total shares.
Morgan Stanley & Co. LLC holds 643.00 shares, accounting for 0.01% of the total shares.
Intracoastal Capital, L.L.C. holds 3.13K shares, accounting for 0.07% of the total shares.
Rhumbline Advisers Ltd. Partnership holds 4.28K shares, accounting for 0.10% of the total shares.
What are the top three shareholder types of BioLine RX Ltd?
The top three shareholder types of BioLine RX Ltd are:
Hong Seng Technology Ltd
Citadel Advisors LLC
UBS Financial Services, Inc.
Hong Seng Technology Ltd
Citadel Advisors LLC
UBS Financial Services, Inc.
How many institutions hold shares of BioLine RX Ltd (BLRX)?
As of 2025Q4, 62 institutions hold shares of BioLine RX Ltd, with a combined market value of approximately 27.70K, accounting for 3.92% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.13%.
What is the biggest source of revenue for BioLine RX Ltd?
In --, the -- business generated the highest revenue for BioLine RX Ltd, amounting to -- and accounting for --% of total revenue.
